Telomir Pharmaceuticals (NASDAQ:TELO) announced on Wednesday, preclinical findings demonstrating that Telomir-1 reduces tumor size by approximately 50% in a prostate cancer animal model using highly ...

This groundbreaking finding suggests that Telomir-1 may selectively benefit healthy cells while suppressing malignant growth, challenging the assumption that telomere-elongating drugs inherently ...

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Thymic carcinoma, a rare cancer, is often associated with poor prognosis in advanced or recurrent stages. However, its rarity ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.

Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and ...

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

In this video, Michael Cecchini, MD, discusses results of two clinical trials evaluating pamrevlumab in pancreatic cancer, which were presented at ASCO Gastrointestinal Cancers Symposium.